159 related articles for article (PubMed ID: 37108784)
1. APC Loss Prevents Doxorubicin-Induced Cell Death by Increasing Drug Efflux and a Chemoresistant Cell Population in Breast Cancer.
Stefanski CD; Arnason A; Maloney S; Kotsen J; Powers E; Zhang JT; Prosperi JR
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108784
[TBL] [Abstract][Full Text] [Related]
2. NFκBP65 transcription factor modulates resistance to doxorubicin through ABC transporters in breast cancer.
Velaei K; Samadi N; Soltani S; Barazvan B; Soleimani Rad J
Breast Cancer; 2017 Jul; 24(4):552-561. PubMed ID: 27878697
[TBL] [Abstract][Full Text] [Related]
3. Multidrug resistance mediated by ABC transporters in osteosarcoma cell lines: mRNA analysis and functional radiotracer studies.
Gomes CM; van Paassen H; Romeo S; Welling MM; Feitsma RI; Abrunhosa AJ; Botelho MF; Hogendoorn PC; Pauwels E; Cleton-Jansen AM
Nucl Med Biol; 2006 Oct; 33(7):831-40. PubMed ID: 17045162
[TBL] [Abstract][Full Text] [Related]
4. APC selectively mediates response to chemotherapeutic agents in breast cancer.
VanKlompenberg MK; Bedalov CO; Soto KF; Prosperi JR
BMC Cancer; 2015 Jun; 15():457. PubMed ID: 26049416
[TBL] [Abstract][Full Text] [Related]
5. Effect of β-elemene on the kinetics of intracellular transport of d-luciferin potassium salt (ABC substrate) in doxorubicin-resistant breast cancer cells and the associated molecular mechanism.
Tang CY; Zhu LX; Yu JD; Chen Z; Gu MC; Mu CF; Liu Q; Xiong Y
Eur J Pharm Sci; 2018 Jul; 120():20-29. PubMed ID: 29704644
[TBL] [Abstract][Full Text] [Related]
6. Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer.
Kovalev AA; Tsvetaeva DA; Grudinskaja TV
Exp Oncol; 2013 Dec; 35(4):287-90. PubMed ID: 24382439
[TBL] [Abstract][Full Text] [Related]
7. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
[TBL] [Abstract][Full Text] [Related]
8. APC loss in breast cancer leads to doxorubicin resistance via STAT3 activation.
VanKlompenberg MK; Leyden E; Arnason AH; Zhang JT; Stefanski CD; Prosperi JR
Oncotarget; 2017 Nov; 8(61):102868-102879. PubMed ID: 29262529
[TBL] [Abstract][Full Text] [Related]
9. Cell density modulates chemoresistance in breast cancer cells through differential expression of ABC transporters.
Shivhare S; Das A
Mol Biol Rep; 2023 Jan; 50(1):215-225. PubMed ID: 36319789
[TBL] [Abstract][Full Text] [Related]
10. siRNAs targeting multidrug transporter genes sensitise breast tumour to doxorubicin in a syngeneic mouse model.
Tiash S; Chowdhury EH
J Drug Target; 2019 Mar; 27(3):325-337. PubMed ID: 30221549
[TBL] [Abstract][Full Text] [Related]
11. Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.
Stein U; Lage H; Jordan A; Walther W; Bates SE; Litman T; Hohenberger P; Dietel M
Int J Cancer; 2002 Feb; 97(6):751-60. PubMed ID: 11857350
[TBL] [Abstract][Full Text] [Related]
12. Combination of 7-
Chen Y; Li X; Shi L; Ma P; Wang W; Wu N; Gan Y; Han X; Huang S; Kang X; Liu S; Zhen Y
Aging (Albany NY); 2022 Sep; 14(17):7156-7169. PubMed ID: 36107024
[TBL] [Abstract][Full Text] [Related]
13. APC loss affects DNA damage repair causing doxorubicin resistance in breast cancer cells.
Stefanski CD; Keffler K; McClintock S; Milac L; Prosperi JR
Neoplasia; 2019 Dec; 21(12):1143-1150. PubMed ID: 31759252
[TBL] [Abstract][Full Text] [Related]
14. Vielanin P enhances the cytotoxicity of doxorubicin via the inhibition of PI3K/Nrf2-stimulated MRP1 expression in MCF-7 and K562 DOX-resistant cell lines.
Gao HL; Xia YZ; Zhang YL; Yang L; Kong LY
Phytomedicine; 2019 May; 58():152885. PubMed ID: 31009836
[TBL] [Abstract][Full Text] [Related]
15. Icariin enhances cytotoxicity of doxorubicin in human multidrug-resistant osteosarcoma cells by inhibition of ABCB1 and down-regulation of the PI3K/Akt pathway.
Wang Z; Yang L; Xia Y; Guo C; Kong L
Biol Pharm Bull; 2015; 38(2):277-84. PubMed ID: 25747987
[TBL] [Abstract][Full Text] [Related]
16. Effect of MDR modulators verapamil and promethazine on gene expression levels of MDR1 and MRP1 in doxorubicin-resistant MCF-7 cells.
Dönmez Y; Akhmetova L; İşeri ÖD; Kars MD; Gündüz U
Cancer Chemother Pharmacol; 2011 Apr; 67(4):823-8. PubMed ID: 20563580
[TBL] [Abstract][Full Text] [Related]
17. Forced expression of heat shock protein 27 (Hsp27) reverses P-glycoprotein (ABCB1)-mediated drug efflux and MDR1 gene expression in Adriamycin-resistant human breast cancer cells.
Kanagasabai R; Krishnamurthy K; Druhan LJ; Ilangovan G
J Biol Chem; 2011 Sep; 286(38):33289-300. PubMed ID: 21784846
[TBL] [Abstract][Full Text] [Related]
18. ATP-dependent activity and mitochondrial localization of drug efflux pumps in doxorubicin-resistant breast cancer cells.
Dartier J; Lemaitre E; Chourpa I; Goupille C; Servais S; Chevalier S; Mahéo K; Dumas JF
Biochim Biophys Acta Gen Subj; 2017 May; 1861(5 Pt A):1075-1084. PubMed ID: 28214549
[TBL] [Abstract][Full Text] [Related]
19. miR-145 sensitizes breast cancer to doxorubicin by targeting multidrug resistance-associated protein-1.
Gao M; Miao L; Liu M; Li C; Yu C; Yan H; Yin Y; Wang Y; Qi X; Ren J
Oncotarget; 2016 Sep; 7(37):59714-59726. PubMed ID: 27487127
[TBL] [Abstract][Full Text] [Related]
20. Increasing the cytotoxicity of doxorubicin in breast cancer MCF-7 cells with multidrug resistance using a mesoporous silica nanoparticle drug delivery system.
Wang X; Teng Z; Wang H; Wang C; Liu Y; Tang Y; Wu J; Sun J; Wang H; Wang J; Lu G
Int J Clin Exp Pathol; 2014; 7(4):1337-47. PubMed ID: 24817930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
